key: cord-1008197-ckgt3qyf
authors: Hong, Sun In; Ryu, Byung-Han; Hong, Kyung-Wook; Bae, In-Gyu; Cho, Oh-Hyun
title: Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
date: 2022-03-10
journal: Infect Chemother
DOI: 10.3947/ic.2021.0143
sha: 32e8877e9b2f941f4f9006cec49cadd8a77d554d
doc_id: 1008197
cord_uid: ckgt3qyf

BACKGROUND: Real-world clinical data concerning regdanvimab, a monoclonal antibody treatment for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), are urgently needed. Here, we describe our experience with regdanvimab. MATERIALS AND METHODS: This retrospective cohort study enrolled high-risk adults with mild-to-moderate COVID-19 who were admitted to a dedicated COVID-19 hospital in Korea from March to September 2021. We used multiple logistic regression and propensity score-matching to compare the outcomes of patients who did or did not receive regdanvimab. The primary outcome was in-hospital progression to severe or critical status, or death. RESULTS: Of 586 patients eligible for regdanvimab, 256 patients who received regdanvimab and 251 untreated patients were included. The median age was 66 years and 47.5% were men. The most common underlying illnesses were hypertension (53.8%) and diabetes (36.9%). Patients were admitted to the hospital at a median of 2 days after symptom onset; regdanvimab was administered at a median of 3 days after symptom onset. Multivariate analysis indicated that regdanvimab significantly reduced the risk of disease progression during hospitalization [odds ratio (OR): 0.285; 95% confidence interval (CI): 0.144 - 0.564]. In a 1:1 propensity score-matched cohort (172 patients in either group), regdanvimab also decreased the risk of progression (OR: 0.162; 95% CI: 0.068 - 0.386). CONCLUSION: In high-risk patients with mild-to-moderate COVID-19, regdanvimab decreased the risk of progression to severe COVID-19.

Although more than 1 year has passed since the World Health Organization declared coronavirus disease 2019 to be a global pandemic, hundreds of thousands of daily cases and thousands of daily deaths continue to be reported worldwide [1] . Most patients

This observational cohort study was conducted at Masan Medical Center (MMC), a 300-bed public hospital in Changwon, Gyeongsangnam-do Province (population 3.5 million), Korea. MMC has operated as a dedicated hospital for patients with mild-to-moderate COVID-19 since February 2020. During the study period, all adult COVID-19 cases were hospitalized immediately or transported to residential treatment centers for treatment and isolation. MMC provided treatment for patients who required low-flow oxygen therapy; severe or critical patients who required high-flow therapy or mechanical ventilation were transferred to university hospitals. Patients were discharged if they met the clinical or testing criteria of the Korean Government. In the clinical criteria, any symptomatic case must not have fever in the absence of fever reducers and other clinical symptoms must improve for at least 72 h after 10 days from symptom onset. Asymptomatic patients were discharged if they lacked any clinical symptoms for 10 days. The testing criteria required cases to be polymerase chain reaction test-negative twice, with at least 24 h between the tests [13] .

The indications for regdanvimab (Celltrion, as conditionally approved by the MFDS) were adults (age >60 years) with mild COVID-19 and at least one of diabetes mellitus, hypertension, cardiovascular disease, or chronic lung disease; or radiologically confirmed pneumonia (regardless of concomitant risk factors). To allow comparisons with other studies, we modified the clinical criteria based on the recommendations of the United States Food and Drug Administration (US FDA). Our clinical criteria were mild-to-moderate COVID-19 developing within 10 days of symptom onset, and at least one of age ≥65 years or diabetes mellitus; or age >55 years with hypertension, cardiovascular disease, or chronic lung disease. All consenting patients received a single intravenous infusion of 40 mg/kg regdanvimab over 90 min. Patients with severe COVID-19 received steroids and remdesivir. Regdanvimab became available at MMC on March 15, 2021. We included adults hospitalized from March 1, 2021, to September 30, 2021, with laboratory-confirmed (reverse transcriptase polymerase chain reaction) COVID-19 who met the above clinical criteria. We compared patients who received and did not receive regdanvimab. We reviewed medical records (demographics, chronic health conditions, COVID-19 vaccination status, symptoms, laboratory findings, and disease severity at admission). The disease severity at admission was classified based on the National Institute of Health guidelines: mild, symptoms and signs without evidence of lower respiratory tract disease; moderate, symptoms with radiologically confirmed pneumonia but no hypoxemia; severe, respiratory rate >30 breaths/min, oxygen saturation <94.0% on room air at sea level, PaO 2 /FiO 2 <300 mmHg, or lung infiltrates >50.0%; Critical cases were patients who had respiratory failure, septic shock, and/or multiorgan failure [14] . Patients who had clinical manifestations of severe COVID-19 within 2 days of hospitalization and those who received both regdanvimab and oxygen (within 6 h after monoclonal antibody treatment) were excluded because regdanvimab was unlikely to exert any effects in such patients [15] . Patients with incomplete medical records were also excluded. The primary outcome was progression of asymptomatic-to-moderately ill COVID-19 patients to severe or critical status during hospitalization. The duration of hospitalization, transfers to university hospitals, and deaths during hospitalization were also evaluated.

The study protocol was approved by the Gyeongsang National University Changwon Hospital Institutional Review Board (GNUCH no. 2021-07-039). Informed consent was waived because of the retrospective nature of the study.

Baseline characteristics are summarized using standard descriptive statistics. Continuous variables were compared using the Mann-Whitney U-test; categorical variables were compared using the χ 2 test or Fisher's exact test, as appropriate. Univariate analysis was performed to identify variables significantly associated with COVID-19 progression. All variables with P-values <0.1 on univariate analysis, and other significant parameters (vaccination status and regdanvimab treatment), were included in multivariate logistic regression to identify risk factors for disease progression. Physicians tended to prescribe the monoclonal antibody for patients with more severe symptoms ( Table 1) . Thus, we used propensity score-matching to adjust for differences in baseline characteristics; we sought to reduce selection bias and confounding. Nearest-propensity score-matching (without replacement; ratio 1: 1; and caliper = 0.25) between the treatment and control groups was based on age (<65 and ≥65 years); sex; body mass index (BMI) (BMI <30 and ≥30 kg/m 2 ); comorbidities (diabetes, hypertension, chronic lung disease, cerebrovascular disease, cardiovascular disease, or malignancy); COVID-19 severity; vaccination status; and body temperature and symptoms on admission. Comorbidities with <5 cases were not included. Covariate balances in the matched cohort were evaluated using standardized mean differences [16] . Additional multivariate logistic analysis was performed to identify risk factors for COVID-19 disease progression in the propensity score-matched cohort. Kaplan-Meier curves were drawn to compare the outcomes of the two groups using the logrank test. To evaluate the effect of regdanvimab on SARS-CoV-2 B.1.617.2 (Delta) variants indirectly, subgroup analyses were performed with similar approaches by dividing before and after July 2021, when the Delta variant became dominant (the "fourth wave"). All tests were two-tailed, and a P-value <0.05 was considered statistically significant. All analyses were performed using SPSS software (version 24.0, IBM Corporation, Armonk, NY, USA) and R software (version 4.1.1 with the R packages; The R Project for Statistical Computing, Vienna, Austria).

https://doi.org/10.3947/ic.2021.0143 https://icjournal.org 

Days from diagnosis to admission, median (range) 

Of 2,236 adults admitted to MMC, 586 had at least one risk factor rendering monoclonal antibody treatment appropriate. In total, 507 patients were included in the analysis: a monoclonal antibody group (n = 256) and a control group (n = 251). Furthermore, 79 patients met the exclusion criteria (Fig. 1) . The baseline characteristics of both groups are listed in Table 1 . The median age was 66 years (interquartile range, 60 -72 years) and 47.5% of the patients were men. The most common underlying illnesses were hypertension (53.8%), diabetes (36.9%), coronary artery disease (9.1%), cerebrovascular disease (6.9%), and chronic lung disease (3.7%). Patients were admitted to the hospital at a median of 2 days (range, 0 -9 days) from symptom onset, indicating admission on the day of diagnosis (median, 0 days; range, 0 -4 days). Regdanvimab was administered at a median of 3 days (range, 0 -9 days) from symptom onset and at a median of 1 day (range, 0 -7 days) from admission. Before matching (compared with controls), the treatment group exhibited more COVID-19 symptoms, more chronic lung disease, more temperatures >38°C on admission, and more cases of moderate COVID-19 on admission. Propensity score-matching yielded 172 patients in each group. The baseline characteristics were adequately balanced, as revealed by the standardized mean differences (Supplementary Table 1 and Fig. 1 ).

Progression to severe COVID-19 occurred in 20 (7.8%) monoclonal antibody-treated patients and 31 (12.4%) untreated patients (P = 0.089), including 3 of each pre-matched cohort who were transferred to university hospitals. There were no deaths. Although the duration of hospitalization slightly differed between the pre-matched groups, this difference Patients with one of the following risk factors of progression to severe COVID-(n = ) -Age ≥ years, diabetes mellitus, patients years and older with hypertension, cardiovascular disease, or chronic lung disease disappeared after propensity score-matching (P = 0.329) ( Table 1) . After adjustments for age, hypertension status, body temperature on admission, C-reactive protein (CRP) level, platelet count, COVID-19 vaccination status, and disease severity, regdanvimab was significantly associated with a reduced risk of disease progression during hospitalization [odds ratio (OR), 0.285; 95% confidence interval (CI), 0.144 -0.564]. Hypertension, CRP level ≥1 mg/dL, platelet count <150 × 10 3 /mm 3 and moderate disease severity on admission were significantly associated with disease progression ( Table 2 ). In the propensity score-matched cohort, progression to severe COVID-19 occurred in 8 (4.7%) monoclonal antibody-treated patients and 30 (17.4%) untreated patients (P <0.001), including 1 and 3 patients (respectively) who were transferred to university hospitals ( Table 1) . After adjustments for hypertension, body temperature on admission, CRP level, platelet count, COVID-19 vaccination status, and disease severity, regdanvimab significantly reduced the risk of disease progression during hospitalization (OR: 0.162; 95% CI: 0.068 -0.386) in the propensity score-matched cohort ( Table 2) . Kaplan-Meier survival analysis also revealed a significant difference in disease progression within 2 weeks after hospitalization between the two groups (log-rank test P <0.001; Fig. 2B ).

https://doi.org/10.3947/ic.2021.0143 https://icjournal.org Log-rank test P-value < . (Supplementary Table 2, 3) . We noted no serious adverse infusion-related events among regdanvimab-treated patients during the study period.

In this retrospective study, we found that regdanvimab treatment of mild-to-moderate COVID-19 was significantly associated with a decreased risk of progression to severe disease during hospitalization. It is difficult to compare the effect of regdanvimab to the effects of other neutralizing antibody therapies approved by the US FDA (i.e., bamlanivimabetesevimab, casirivimab-imdevimab, and sotrovimab) because of differences in the clinical settings and outcome measures. We included only patients who met the US FDA criteria for monoclonal antibody use. Our results are consistent with previous reports that monoclonal antibody treatment prevented mild-to-moderate COVID-19 from progressing to severe disease (i.e., hospitalization) by 70.0 -80.0% [17] .

Unlike other monoclonal antibodies, limited data are available concerning regdanvimab. One Phase II trial reported that the proportions of patients requiring hospitalization or oxygen to day 28 were 4.0% and 4.9% in regdanvimab 40 and 80 mg/kg groups, but 8.7% in a placebo group. A preliminary Phase III trial found that regdanvimab reduced the risk of hospitalization or death with 28 days by 72% (compared to placebo) in high-risk patients with mild-to-moderate COVID-19 (P <0.01) [18] . We found that regdanvimab was useful for treating mild-to-moderate COVID-19 in a real-world setting.

In one randomized controlled trial, bamlanivimab was no better than standard therapy in hospitalized COVID-19 patients; the primary outcome was sustained recovery over a 90day period [19] . Of 314 patients, 77.0% exhibited a disease status exceeding "severe" and monoclonal antibodies were administered at a median of 7 days from symptom onset. Based on this work and other clinical trials, the US guideline recommends monoclonal antibody treatment for ambulatory at-risk patients with mild-to-moderate COVID-19 [20] . Although our primary outcome was progression to severe COVID-19 in hospitalized patients with mildto-moderate COVID-19, we acknowledge that it is difficult to directly compare our results with the results of previous studies that employed hospitalization or emergency room visits as primary outcomes [17] .

As SARS-CoV-2 variants such as Delta and Omicron, there has been increasing concern that monoclonal antibody effects will decrease. An in vitro study showed that bamlanivimab was not active against the Delta variant, while etesevimab, casirivimab, and imdevimab remained active [21] . In vitro and in a mouse model, regdanvimab was active against Delta, but showed less activity than it did against Delta precursors [22] . However, we found that the preventive effect of regdanvimab appeared to decrease during the Delta variant-dominant wave.

Importantly, it is difficult to draw firm conclusions because more patients became vaccinated and there were a relatively small number of cases during the Delta variant-dominant wave. Furthermore, we do not know the proportions of Delta-infected cases; genomic sequencing data were lacking. According to the Korea Disease Control and Prevention Agency, >50.0% of random samples collected in mid-July and >90.0% collected in early August were Delta. It may thus be possible to compare the effect of regdanvimab before and after the Delta variantdominant wave in this study. Omicron is rapidly outpacing Delta globally and is driving an upsurge of infections in most regions [23] . In vitro data suggest that several monoclonal antibodies, including regdanvimab, lost neutralizing activity against Omicron [24] . Although some monoclonal antibodies in clinical use may retain benefit, the use of monoclonal antibody therapeutics will require caution depending on whether Omicron is dominant in a region [25] .

Our work had several limitations. First, although propensity score-matching was used to reduce selection bias and confounding, many cases were discarded during this process, possibly creating (rather than eliminating) selection bias. However, multiple logistic regression analysis yielded similar results. Second, we excluded patients who progressed to severe or critical status within 2 days of hospitalization or within 6 h of regdanvimab administration. Because progression to severe or critical COVID-19 disease usually occurred soon after hospitalization, such patients were less likely to receive regdanvimab; this may have exaggerated the effect of the drug. We excluded such patients to render our analysis conservative. Third, neither the duration of hospitalization nor the time to symptom improvement served as a principal outcome, because patients were discharged only when they met the government guideline regardless of whether they had recovered earlier. Finally, minor symptoms might not have been recorded by attending physicians or nurses.

In conclusion, our real-world study suggests that regdanvimab treatment of mild-tomoderate COVID-19 significantly reduced disease progression; the effect appeared to wane during the Delta variant-dominant wave. A large-scale prospective study or randomized clinical trial is needed to explore the effects of regdanvimab in the era of Omicron domination and high numbers of vaccinated individuals.

WHO coronavirus (COVID-19) dashboard

Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study

Mild or moderate Covid-19

Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab

Yancopoulos GDTrial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

Bamlanivimab plus etesevimab in mild or moderate Covid-19

Skovronsky DMBLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

Monoclonal antibodies for prevention and treatment of COVID-19

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59

Press release: Celltrion's regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean MFDS

EMA issues advice on use of regdanvimab for treating COVID-19

Republic of Korea. Patient treatment & management

COVID-19 treatment guidelines. Clinical spectrum of SARS-CoV-2 infection

Effect of monoclonal antibody treatment on clinical outcomes in ambulatory patients with coronavirus disease 2019

Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research

Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection

Regdanvimab: First approval

A Neutralizing monoclonal antibody for hospitalized patients with Covid-19

IDSA guidelines on the treatment and management of patients with COVID-19

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

529)-technical-brief-and-priority-actions-for-member-states

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant

Association of clinical characteristics and disease progression in the pre-matched cohort with COVID-19 before and after the Delta variant-dominant wave in Korea Click here to view Supplementary Table 3 Association of clinical characteristics and disease progression in the propensity scorematched cohort with COVID-19 before and after the Delta variant-dominant wave in Korea Click here to view Supplementary Figure 1 Visualization of the distribution of propensity score by the jitter plot.